Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: A new approach for an old neurotoxin

Neurotoxicity Research

Volumn 21, Issue 3, 2012, Pages 291-301

  Moreira, Camila G ^a   Barbiero, Janaína K ^a   Ariza, Deborah ^a   Dombrowski, Patrícia A ^a   Sabioni, Pamela ^a   Bortolanza, Mariza ^a   Da Cunha, Claudio ^a   Vital, Maria A B F ^a   Lima, Marcelo M S ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Dopamine; Intranigral; Parkinson's disease; Rotenone; Substantia nigra pars compacta

Indexed keywords

DOPAMINE; NEUROTOXIN; ROTENONE; SEROTONIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEARNING DISORDER; LOCOMOTION; MALE; MEMORY DISORDER; MENTAL TEST; METABOLITE; MOTOR DYSFUNCTION; NERVE CELL; NERVE DEGENERATION; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; AVOIDANCE LEARNING; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; EXPLORATORY BEHAVIOR; HYDROXYINDOLEACETIC ACID; MALE; MICROINJECTIONS; MOTOR ACTIVITY; NERVE DEGENERATION; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; ROTENONE; SEROTONERGIC NEURONS; SEROTONIN; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; UNCOUPLING AGENTS;

ANIMALIA; RODENTIA;

EID: 84861459037     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-011-9278-3     Document Type: Article

References (46)

1. Alam M, Schmidt WJ (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136:317-324 (Pubitemid 35246417)
2. Alam M, Schmidt WJ (2004) L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behav Brain Res 153:439-446 (Pubitemid 38953119)
3. Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romaska I, Bojarski A, Vetulani J (2004) Protective effect of 1-methyl-1,2,3,4- tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 7:155-163 (Pubitemid 38823282)
4. Ariza D, Lima MMS, Moreira CG, Dombrowski PA, Avila TV, Allemand A, Mendes DA, Da Cunha C, Vital MABF (2010) Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease. Neurochem Res 35:1620-1627
5. Barbiero JK, Santiago RM, Lima MMS, Ariza D, Morais LH, Andreatini R, Vital MABF (2010) Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav Brain Res 216:186-192
6. Bavaresco CS, Chiarani F, Duringon E, Ferro MM, Da Cunha C, Netto CA, Wyse AT (2007) Intrastriatal injection of hypoxanthine reduces striatal serotonin content and impairs spatial memory performance in rats. Metab Brain Dis 22:67-76 (Pubitemid 46354825)
7. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306
8. Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, Cookson MR, Greenamyre JT (2006) Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 22:404-420 (Pubitemid 44294281)
9. Biehlmaier O, Alam M, Schmidt WJ (2007) A rat model of Parkinsonism shows depletion of dopamine in the retina. Neurochem Int 50:189-195 (Pubitemid 44879675)
10. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT (2009) A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 34:279-290
11. Choi DY, Liu M, Hunter RL, Cass WA, Pandya JD, Sullivan PG, Shin EJ, Kim HC, Gash DM, Bing G (2009) Striatal neuroinflammation promotes Parkinsonism in rats. PLoS ONE 4:e5482
12. Da Cunha C, Wietzikoski EC, Dombrowski PA, Bortolanza M, Santos LM, Boschen SL, Miyoshi E (2009) Learning processing in the basal ganglia: a mosaic of broken mirrors. Behav Brain Res 199:157-170
13. Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-317 (Pubitemid 34634286)
14. Drolet RE, Cannon JR, Montero L, Greenamyre JT (2009) Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 36:96-102
15. Ferrante RJ, Schulz JB, Kowall NW, Beal MF (1997) Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 753:157-162 (Pubitemid 27156146)
16. Gaspar P, Febvret A, Colombo J (1993) Serotonergic sprouting in primate MTP-induced hemiparkinsonism. Exp Brain Res 96: 100-106 (Pubitemid 23332183)
17. Greenamyre JT, Betarbet R, Sherer TB (2003) The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord 9(Suppl 2):S59-S64 (Pubitemid 36952523)
18. Hsieh PF, Chia LG, Ni DR, Cheng LJ, Ho YP, Tzeng SF, Chang MH, Hong JS (2002) Behavior, neurochemistry and histology after intranigral lipopolysaccharide injection. Neuroreport 13:277-280 (Pubitemid 34183566)
19. Jenkins TA, Elliott JJ, Ardis TC, Cahir M, Reynolds GP, Bell R, Cooper SJ (2010) Tryptophan depletion impairs object-recognition memory in the rat: reversal by risperidone. Behav Brain Res 208:479-483
20. Lane E, Dunnett S (2008) Animal models of Parkinson's disease and L-dopa induced dyskinesia: How close are we to the clinic? Psychopharmacology (Berl) 199:303-312 (Pubitemid 351938234)
21. Lapointe N, St-Hilaire M, Martinoli MG, Blanchet J, Gould P, Rouillard C, Cicchetti F (2004) Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 18: 717-719
22. Lima MMS, Reksidler AB, Marques Zanata S, Bueno Machado H, Tufik S, Vital MABF (2006) Different Parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 1101:117-125 (Pubitemid 44036768)
23. Lima MMS, Andersen ML, Reksidler AB, Vital MABF, Tufik S (2007) The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE 2:e513
24. Lima MMS, Reksidler AB, Vital MABF (2009) The neurobiology of the substantia nigra pars compacta: from motor to sleep regulation. J Neural Transm Suppl 73:135-145
25. Maeda T, Kannari K, Shen H, Arai A, Tomiyama M, Matsunaga M, Suda T (2003) Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci Lett 343:17-20 (Pubitemid 36577202)
26. Mitchell ES, McDevitt RA, Neumaier JF (2009) Adaptations in 5-HT receptor expression and function: implications for treatment of cognitive impairment in aging. J Neurosci Res 87:2803-2811
27. Navailles S, Bioulac B, Gross C, De Deurwaerdere P (2010) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 38:136-143
28. Nehru B, Verma R, Khanna P, Sharma SK (2008) Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. Brain Res 1201:122-127
29. Norazit A, Meedeniya AC, Nguyen MN, Mackay-Sim A (2010) Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle. Brain Res 1360:119-129
30. Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates, 5th edn. Academic Press, San Diego
31. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN (2006) The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 202:391-403 (Pubitemid 44692682)
32. Ravenstijn PG, Merlini M, Hameetman M, Murray TK, Ward MA, Lewis H, Ball G, Mottart C, de Ville de Goyet C, Lemarchand T, van Belle K, O'Neill MJ, Danhof M, de Lange EC (2008) The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. J Pharmacol Toxicol Methods 57:114-130
33. Reksidler AB, Lima MMS, Zanata SM, Machado HB, Da Cunha C, Andreatini R, Tufik S, Vital MABF (2007) The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 560:163-175 (Pubitemid 46341312)
34. Reksidler AB, Lima MMS, Dombrowski PA, Andersen ML, Zanata SM, Andreatini R, Tufik S, Vital MABF (2008) Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease. J Neurosci Methods 167:268-277 (Pubitemid 350235638)
35. Reksidler AB, Lima MMS, Dombrowski PA, Barnabé GF, Andersen ML, Tufik S, Vital MABF (2009) Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease. J Neural Transm Suppl 73:259-268
36. Santiago RM, Barbiero JK, Lima MMS, Dombrowski PA, Andreatini R, Vital MABF (2010) Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 34:1104-1114
37. Saravanan KS, Sindhu KM, Mohanakumar KP (2005) Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res 1049:147-155 (Pubitemid 41072930)
38. Schmidt WJ, Alam M (2006) Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). J Neural Transm Suppl 70:273-276 (Pubitemid 44622211)
39. Schmitz C, Hof PR (2000) Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach. J Chem Neuroanat 20:93-114
40. Segura Aguilar J, Kostrzewa RM (2004) Neurotoxins and neurotoxic species implicated in neurodegeneration. Neurotox Res 6: 615-630
41. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT (2003) Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23:10756-10764 (Pubitemid 37499681)
42. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN (2008) Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 156:830-840
43. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100:5473-5478 (Pubitemid 36542729)
44. Thiffault C, Langston JW, Di Monte DA (2000) Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res 885:283-288
45. Zeng BY, Iravani MM, Jackson MJ, Rose S, Parent A, Jenner P (2010) Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol Dis 40:599-607
46. Zhou FC, Bledsoe S, Murphy J (1991) Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 556:108-116